Lupin Collaborates with ERN for Luforbec® (beclometasone/formoterol) pMDI Launch in Spain

Global pharma major Lupin Limited (Lupin) today announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain.

This collaboration combines Lupin's global respiratory expertise and proven pMDI manufacturing excellence and ERN's robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.

Thierry Volle, President EMEA and Emerging Markets, Lupin said, "The launch of Luforbec® in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care. Together, we are building something truly exciting for patients and healthcare professionals."

"Partnering with Lupin allows us to bring a proven, high‑value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area," said David Solanes, CEO of LABORATORIOS ERN, S.A.

Shares of Lupin Limited was last trading in BSE at Rs. 2268.10 as compared to the previous close of Rs. 2248.70. The total number of shares traded during the day was 90454 in over 9440 trades.

The stock hit an intraday high of Rs. 2305.75 and intraday low of 2260.95. The net turnover during the day was Rs. 206248592.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals ERN Collaboration Luforbec